Apogee Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2022-01-01
- Employees
- 91
- Market Cap
- $2.6B
- Introduction
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Apogee Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06920901
- Locations
- 🇺🇸
Allergy and Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States
🇺🇸University of Kansas School of Medicine, Kansas City, Missouri, United States
🇺🇸Sneeze, Wheeze & Itch Associates, Normal, Illinois, United States
A Study Evaluating APG777 in Atopic Dermatitis
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Apogee Therapeutics, Inc.
- Target Recruit Count
- 391
- Registration Number
- NCT06395948
- Locations
- 🇩🇪
Investigational site #55, Hamburg, Germany
🇩🇪Investigational site #60, Berlin, Germany
🇨🇦Investigational site #52, Ajax, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath